ROCKVILLE, Md. & EDMONTON, Alberta, June 14, 2024--Aurinia Announces 2024 Annual General Meeting Results
Key Insights Aurinia Pharmaceuticals will host its Annual General Meeting on 14th of June CEO Peter Greenleaf's total...
ROCKVILLE, Md. & EDMONTON, Alberta, June 05, 2024--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), today announced an oral presentation at the European Alliance of Associations for Rheumatology (EULAR) 2024 taking place in Vienna, Austria June 12-15. The data reinforces previous findings from the AURORA Clinical Program on the safety and effectiveness of LUPKYNIS® (voclosporin), a second generation calcineurin inhibitor (CNI), for the treatment of adult patients with active